Potential New Tourette Syndrome Treatments: Will Real-Time Neurofeedback Have a Role?

Barbara J. Coffey

doi:10.1016/j.biopsych.2020.04.007

Potential New Tourette Syndrome Treatments: Will Real-Time Neurofeedback Have a Role?

Barbara J. Coffey

Research output: Contribution to journal › Comment/debate

2 Scopus citations

Original language	English
Pages (from-to)	1019-1021
Number of pages	3
Journal	Biological Psychiatry
Volume	87
Issue number	12
DOIs	https://doi.org/10.1016/j.biopsych.2020.04.007
State	Published - 15 Jun 2020
Externally published	Yes

Access to Document

10.1016/j.biopsych.2020.04.007

Cite this

@article{96cb517b15a343aeab31c1a7e34330f9,

title = "Potential New Tourette Syndrome Treatments: Will Real-Time Neurofeedback Have a Role?",

author = "Coffey, {Barbara J.}",

note = "Funding Information: BJC is on the Scientific Advisory Board of Abide Therapeutics and Teva/Nuvelution, has received honoraria from the American Academy of Child and Adolescent Psychiatry, Partners Healthcare, Harvard Medical School, Teva, CME Outfitters, University of Cincinnati, University of Texas Medical Branch, and University of Florida, and has received research support from Teva/Nuvelution, Inc., Neurocrine Biosciences , Emalex, the National Institute of Mental Health (Grant No. 5R01MH115959-02), and University of California San Francisco. BJC is co-chair of the Medical Advisory Board of the Tourette Association of America, is on the advisory board for Skyland Trail, and is on the speakers{\textquoteright} bureau for the Tourette Association of America–Centers for Disease Control and Prevention partnership. Funding Information: BJC is on the Scientific Advisory Board of Abide Therapeutics and Teva/Nuvelution, has received honoraria from the American Academy of Child and Adolescent Psychiatry, Partners Healthcare, Harvard Medical School, Teva, CME Outfitters, University of Cincinnati, University of Texas Medical Branch, and University of Florida, and has received research support from Teva/Nuvelution, Inc. Neurocrine Biosciences, Emalex, the National Institute of Mental Health (Grant No. 5R01MH115959-02), and University of California San Francisco. BJC is co-chair of the Medical Advisory Board of the Tourette Association of America, is on the advisory board for Skyland Trail, and is on the speakers? bureau for the Tourette Association of America?Centers for Disease Control and Prevention partnership. I thank Maria Cruz for her editorial assistance with preparation of the manuscript.",

year = "2020",

month = jun,

day = "15",

doi = "10.1016/j.biopsych.2020.04.007",

language = "English",

volume = "87",

pages = "1019--1021",

journal = "Biological Psychiatry",

issn = "0006-3223",

publisher = "Elsevier Inc.",

number = "12",

}

TY - JOUR

T1 - Potential New Tourette Syndrome Treatments

T2 - Will Real-Time Neurofeedback Have a Role?

AU - Coffey, Barbara J.

N1 - Funding Information: BJC is on the Scientific Advisory Board of Abide Therapeutics and Teva/Nuvelution, has received honoraria from the American Academy of Child and Adolescent Psychiatry, Partners Healthcare, Harvard Medical School, Teva, CME Outfitters, University of Cincinnati, University of Texas Medical Branch, and University of Florida, and has received research support from Teva/Nuvelution, Inc., Neurocrine Biosciences , Emalex, the National Institute of Mental Health (Grant No. 5R01MH115959-02), and University of California San Francisco. BJC is co-chair of the Medical Advisory Board of the Tourette Association of America, is on the advisory board for Skyland Trail, and is on the speakers’ bureau for the Tourette Association of America–Centers for Disease Control and Prevention partnership. Funding Information: BJC is on the Scientific Advisory Board of Abide Therapeutics and Teva/Nuvelution, has received honoraria from the American Academy of Child and Adolescent Psychiatry, Partners Healthcare, Harvard Medical School, Teva, CME Outfitters, University of Cincinnati, University of Texas Medical Branch, and University of Florida, and has received research support from Teva/Nuvelution, Inc. Neurocrine Biosciences, Emalex, the National Institute of Mental Health (Grant No. 5R01MH115959-02), and University of California San Francisco. BJC is co-chair of the Medical Advisory Board of the Tourette Association of America, is on the advisory board for Skyland Trail, and is on the speakers? bureau for the Tourette Association of America?Centers for Disease Control and Prevention partnership. I thank Maria Cruz for her editorial assistance with preparation of the manuscript.

PY - 2020/6/15

Y1 - 2020/6/15

UR - http://www.scopus.com/inward/record.url?scp=85084853482&partnerID=8YFLogxK

U2 - 10.1016/j.biopsych.2020.04.007

DO - 10.1016/j.biopsych.2020.04.007

M3 - Comment/debate

C2 - 32498788

AN - SCOPUS:85084853482

SN - 0006-3223

VL - 87

SP - 1019

EP - 1021

JO - Biological Psychiatry

JF - Biological Psychiatry

IS - 12

ER -